Tilman Hohendorf-Schneider

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Distinct Multiomic Signatures of Environmental Exposure Drive Immune Dysregulation and Disease Activity in Early Multiple Sclerosis.

Distinct Multiomic Signatures of Environmental Exposure Drive Immune Dysregulation and Disease Activity in Early Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 26, 2026

Single-cell analysis of skin and blood reveals systemic immune responses to ultraviolet B and their impairment in MS.

Single-cell analysis of skin and blood reveals systemic immune responses to ultraviolet B and their impairment in MS.

Journal: Journal of neuroinflammation

Published: January 27, 2026

Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.

Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.

Journal: Annals of neurology

Published: August 22, 2025

Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition.

Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition.

Journal: Annals of clinical and translational neurology

Published: May 31, 2025

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.

Journal: EBioMedicine

Published: May 30, 2025

B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.

B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.

Journal: iScience

Published: April 04, 2025

Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy.

Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy.

Journal: Cell reports. Medicine

Published: February 21, 2024

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.

Journal: Brain : a journal of neurology

Published: January 30, 2024

Targeting MCAM for next-generation modulation of leucocyte trafficking.

Targeting MCAM for next-generation modulation of leucocyte trafficking.

Journal: Brain : a journal of neurology

Published: February 23, 2023

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 27, 2022

A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis.

A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis.

Journal: Science translational medicine

Published: November 30, 2022

Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Journal: The Journal of experimental medicine

Published: October 28, 2022

Showing 1-12 of 56

Last Updated: 09/26/2026